5-Alpha Reductase Inhibitors for Treatment of Benign Prostatic Hyperplasia: A Systematic Review and Meta-Analysis

Abstract

Introduction: Finasteride and dutasteride are competitive inhibitors of 5-alpha reductase (5AR) enzymes and are commonly used for the treatment of symptomatic benign prostatic hyperplasia (BPH). This study is intended to evaluate the literature regarding the relative efficacy of these two agents on clinically important outcomes.